CAR-T therapies need to overcome current limitations to unlock promising treatment possibilities for…
While CAR-Ts are transforming blood cancer treatment, their struggle in solid tumors highlights the urgent need for innovation in…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CAR-T therapies
Three CAR-T therapies forecasted to capture over 70 per cent of T-Cell immunotherapy market in 2025
GlobalData’s latest report reveals that the TCI space is entering a new growth phase, driven by clinical success and investor…
Blood cancers dominate CAR-T pipeline: GlobalData
According to GlobalData’s Drugs Database, blood cancers account for over half of all CAR-Ts in the active pipeline* and make up…
Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell…
Takeda entered into multiple cell therapy collaborations for the development of CAR-T therapies with organizations like Memorial…
New CAR-T therapies in South Korea to face stringent regulatory oversight: GlobalData
The Korean Ministry of Food and Drug Safety (MFDS) has recently mandated the reporting of any suspected adverse reactions,…
Kite gets US FDA nod for Yescarta to treat relapsed or refractory follicular lymphoma
Yescarta is the first CAR T-Cell therapy approved for indolent follicular lymphoma
Regenerative medicine market to reach $16.4 bn in 2026: GlobalData
There are currently 53 marketed RM products and 175 RM pipeline agents in development in the eight major markets